Over Half of Patients Have Suboptimal Response to Statins
Suboptimal responders have increased risk for incident cardiovascular disease
Cardiovascular and Metabolic Disorders
Evolocumab Increases Apolipoprotein A1 Remnant Ratio After 12 Weeks
This post hoc analysis is the first to suggest that evolocumab increases the apolipoprotein A1 remnant ratio following 12 weeks of treatment.
Impaired Insulin Sensitivity in People Living With HIV Associated With Cognitive Decline
People living with HIV and declining cognition exhibit hyperinsulinemia, as well as abnormal cholesterol and lipid metabolism.
Statin Therapy Underutilized in Treatment-Eligible Adults in the United States
There is an opportunity to increase statin use by improving physician recognition of statin-eligible patients.
Future WTC Lung Injury Predicted by Metabolic Syndrome
Metabolic syndrome biomarkers have been validated as predictors of World Trade Center-related lung injury.
Benefits of Lipid-Lowering Therapy for Ischemic Stroke Prevention Outweigh Concerns
Lipid-lowering was associated with an increased risk for stroke in secondary prevention trials alone.
Icosapent Ethyl sNDA Submitted for Expanded Indication to Reduce Major CV Events
Amarin has submitted a supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) to reduce the risk of major cardiovascular (CV) events in the statin-treated population. Icosapent ethyl is a single-molecule consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. It is currently indicated as an adjunct to diet to reduce triglyceride…
Icosapent Ethyl Reduces Ischemic Event Burden in Statin-Treated Hypertriglyceridemia
Investigators conducted a prespecified analyses to evaluate the extent to which icosapent ethyl decreases total ischemic events.
After Continued Debate, Dietary Cholesterol Linked to Significant Increase in CVD
Higher consumption of dietary cholesterol is significantly associated with a higher risk for incident cardiovascular disease and all-cause mortality among US adults.
Bempedoic Acid Improves Lipid Control When Added to Statin Therapy
Bempedoic acid, an investigational ATP citrate lyase inhibitor, might safely lower low-density lipoprotein cholesterol levels when added to statin therapy.
Next post in Cardiovascular and Metabolic Disorders
